Company news
Tectonic Therapeutic, Inc. (NASDAQ:TECX) news
Tectonic Therapeutic, Inc. news releases on 6ix. Latest, Sep 29, 2026: Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results…
Press releases & updates
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
September 29, 2026
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
September 28, 2026
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
September 3, 2026
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
August 6, 2026
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
June 9, 2026
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
May 7, 2026
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
April 23, 2026
TD Asset Management Inc. Announces TD ETF Distributions
March 19, 2026
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 25, 2026
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
February 23, 2026
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
February 11, 2026
Tectonic Therapeutic to Participate in December Investor Conferences
December 1, 2025
Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
October 29, 2025
Tectonic Therapeutic to Participate in September Investor Conferences
August 28, 2025
Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights
August 7, 2025
Tectonic Therapeutic Joins Russell 3000® Index
June 30, 2025
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
May 17, 2025
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
May 8, 2025
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference
May 7, 2025
Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025
April 15, 2025
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 20, 2025
Tectonic Therapeutic to Participate in March Investor Conferences
February 20, 2025
Tectonic Announces $185 Million Private Placement
February 2, 2025
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
January 29, 2025
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
December 2, 2024
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
November 25, 2024
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
November 10, 2024
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
November 6, 2024
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
October 21, 2024
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
September 18, 2024
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
July 29, 2024
Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer
June 2, 2024
AVROBIO and Tectonic Therapeutic Announce Merger
January 29, 2024
AVROBIO to Explore Strategic Alternatives
July 11, 2023
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
May 21, 2023
AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
AVROBIO Announces Leadership Transition
April 30, 2023
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
March 22, 2023
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
December 6, 2022
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit
November 6, 2022
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 2, 2022
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
October 26, 2022
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
October 17, 2022
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
September 26, 2022
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
September 19, 2022
AVROBIO to Participate in Four Upcoming Investor Conferences in September
August 30, 2022
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
August 8, 2022